[Executive Summary from Expert Consensus on Effectiveness and Safety of IDPP-4 in the Treatment of Patients with Diabetes and COVID-19]

Overview

Journal Endocrinol Diabetes Nutr

Specialties Endocrinology
Nutritional Sciences

Date 2021 Nov 15

PMID 34778721

Authors

Francisco Javier Carrasco-Sanchez

Enrique Carretero-Anibarro

Manuel Angel Gargallo

Ricardo Gomez-Huelgas

Juan Francisco Merino-Torres

Domingo Orozco-Beltran

Pedro Jose Pines Corrales

Manuel Antonio Ruiz Quintero

Affiliations

Soon will be listed here.

Abstract

Background: This consensus aims to clarify the role of Dipeptidyl Peptidase-4 inhibitors (iDPP-4) in managing patients with diabetes during the COVID-19 pandemic.

Materials And Methods: A PubMed bibliographic search was carried out (December 2019-February 2021). Oxford methodology was used for the evaluation of evidence and possible recommendations were established by consensus.

Results: Diabetes appears to be an independent factor in COVID-19 disease (evidence 2b). No increased risk of contagion with iDPP-4 is demonstrated (evidence 2b), and its use has been shown to be safe (evidence 2b). The use of this drug may present a specific benefit in reducing mortality, particularly in in-hospital use (evidence 2a), reducing admission to intensive care units (evidence 2b) and the need for mechanical ventilation (evidence 2b).

Conclusions: The use of iDPP-4 appears to be safe in patients with COVID-19, and quality studies are needed to clarify their possible advantages further.

References

Bassendine M, Bridge S, McCaughan G, Gorrell M . COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?. J Diabetes. 2020; 12(9):649-658. DOI: 10.1111/1753-0407.13052. View

Liu X, Men P, Wang B, Cai G, Zhao Z . Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis. Lipids Health Dis. 2019; 18(1):144. PMC: 6580696. DOI: 10.1186/s12944-019-1086-4. View

Pal R, Banerjee M, Mukherjee S, Bhogal R, Kaur A, Bhadada S . Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis. Ther Adv Endocrinol Metab. 2021; 12:2042018821996482. PMC: 7897812. DOI: 10.1177/2042018821996482. View

Solerte S, DAddio F, Trevisan R, Lovati E, Rossi A, Pastore I . Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care. 2020; 43(12):2999-3006. PMC: 7770266. DOI: 10.2337/dc20-1521. View

Williamson E, Walker A, Bhaskaran K, Bacon S, Bates C, Morton C . Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584(7821):430-436. PMC: 7611074. DOI: 10.1038/s41586-020-2521-4. View

Silverii G, Monami M, Cernigliaro A, Vigneri E, Guarnotta V, Scondotto S . Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily. Nutr Metab Cardiovasc Dis. 2020; 31(2):396-398. PMC: 7528967. DOI: 10.1016/j.numecd.2020.09.028. View

Apicella M, Campopiano M, Mantuano M, Mazoni L, Coppelli A, Del Prato S . COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020; 8(9):782-792. PMC: 7367664. DOI: 10.1016/S2213-8587(20)30238-2. View

Vankadari N, Wilce J . Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect. 2020; 9(1):601-604. PMC: 7103712. DOI: 10.1080/22221751.2020.1739565. View

Kow C, Hasan S . A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19. Therapie. 2021; 76(4):361-364. PMC: 7834767. DOI: 10.1016/j.therap.2020.12.015. View

10.

Mehta P, McAuley D, Brown M, Sanchez E, Tattersall R, Manson J . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033-1034. PMC: 7270045. DOI: 10.1016/S0140-6736(20)30628-0. View

11.

Grenet G, Mekhaldi S, Mainbourg S, Auffret M, Cornu C, Cracowski J . DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials. Diabetes Care. 2021; 44(3):e36-e37. DOI: 10.2337/dc20-2018. View

12.

Bornstein S, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld A . Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020; 8(6):546-550. PMC: 7180013. DOI: 10.1016/S2213-8587(20)30152-2. View

13.

Valencia I, Peiro C, Lorenzo O, Sanchez-Ferrer C, Eckel J, Romacho T . DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?. Front Pharmacol. 2020; 11:1161. PMC: 7426477. DOI: 10.3389/fphar.2020.01161. View

14.

Berbudi A, Rahmadika N, Tjahjadi A, Ruslami R . Type 2 Diabetes and its Impact on the Immune System. Curr Diabetes Rev. 2019; 16(5):442-449. PMC: 7475801. DOI: 10.2174/1573399815666191024085838. View

15.

Hasan S, Kow C, Bain A, Kavanagh S, Merchant H, Hadi M . Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients. Expert Opin Pharmacother. 2020; 22(2):229-240. DOI: 10.1080/14656566.2020.1837114. View

16.

Fadini G, Morieri M, Longato E, Bonora B, Pinelli S, Selmin E . Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study. Diabetes Obes Metab. 2020; 22(10):1946-1950. PMC: 7283835. DOI: 10.1111/dom.14097. View